The impact of ageing and menopause in women with polycystic ovary syndrome

Clinical Endocrinology - Tập 97 Số 3 - Trang 371-382 - 2022
Nafiye Helvacı1, Bülent O. Yildiz2
1Division of Endocrinology and Metabolism, Department of Internal Medicine Hitit University School of Medicine Corum Turkey
2Division of Endocrinology and Metabolism, Hacettepe University School of Medicine, Ankara, Turkey

Tóm tắt

AbstractPolycystic ovary syndrome (PCOS) is a common hormonal, metabolic and reproductive disorder. Women with PCOS at reproductive age have increased risk and prevalence of prediabetes and diabetes and have multiple risk factors for cardiometabolic disease and other comorbidities such as obstructive sleep apnoea, endometrial cancer and mood disorders, which contribute to the overall health burden of the syndrome. However, little is known about the impact of PCOS on long‐term health in ageing women. In this review, we aimed to give an updated overview regarding the long‐term health outcomes of PCOS and their clinical implications in peri‐ and postmenopause. The PCOS phenotype ameliorates with ageing and limited available data suggest that there is no further deterioration in cardiometabolic profile in women with PCOS after menopause. Accordingly, the risk of cardiovascular disease in ageing women with PCOS seems to be no different from those without PCOS and lower than previously anticipated based on their risk during reproductive years. Regarding other comorbidities including sleep apnoea, mood disorders and endometrial cancer, it is difficult to determine the true risk in older women with PCOS due to the confounding factors and lack of long‐term cohort studies. Large, prospective studies on community‐based and well‐phenotyped PCOS cohorts with extended follow‐up into late menopause are needed to confirm these findings.

Từ khóa


Tài liệu tham khảo

10.1016/j.fertnstert.2016.07.1121

10.1093/humrep/des232

10.1530/EJE-14-0253

10.1016/j.fertnstert.2003.10.004

10.1016/j.fertnstert.2016.05.003

10.1016/j.fertnstert.2014.08.001

10.1210/jc.2013-1295

10.1530/EJE-15-0646

10.1111/cen.14193

10.1016/j.rbmo.2020.12.006

10.1093/humrep/15.1.24

10.1097/AOG.0b013e31823f7135

10.1210/jc.2009-0839

10.1016/S0015-0282(99)00641-X

10.1210/jc.2010-0130

10.1016/j.fertnstert.2018.05.004

10.3109/13697137.2012.707385

10.1038/nrdp.2015.4

10.1161/HYPERTENSIONAHA.107.105742

10.1016/j.maturitas.2018.08.009

10.2174/1570161116666180904094149

10.1161/CIRCRESAHA.116.307547

10.1016/j.ogc.2011.05.011

10.1097/GME.0000000000000193

10.1164/rccm.200209-1055OC

10.1016/j.ecl.2015.05.012

10.1093/humupd/dms030

10.1016/j.metabol.2016.01.006

10.1016/j.fertnstert.2018.08.046

10.1111/cen.14117

10.1046/j.1365-2265.2000.01000.x

10.1210/jc.2017-02421

10.1210/jc.2010-2959

10.1210/clinem/dgaa840

10.1093/humrep/des463

10.1093/humupd/dmy007

10.1093/humrep/dew329

10.1210/jc.2017-01354

Anagnostis P, Risk of type 2 diabetes mellitus in polycystic ovary syndrome is associated with obesity: a meta‐analysis of observational studies [published online ahead of print June 26, 2021], Endocrine, ​

10.1016/j.fertnstert.2017.09.004

10.1210/jc.2011-1677

10.1089/jwh.2015.5441

10.1093/hropen/hoz042

10.1016/S0002-9343(01)00948-2

10.1016/j.fertnstert.2010.12.027

10.1093/humrep/15.4.785

Iftikhar S, 2012, Risk of cardiovascular events in patients with polycystic ovary syndrome, Neth J Med, 70, 74

10.1186/s12958-020-00576-1

10.1530/EC-20-0527

Alberti KGMM, 2009, Circulation, 1640

10.1111/obr.12762

10.1210/jc.2013-4170

10.1093/humupd/dmr025

10.1210/jc.87.8.3871

10.1111/j.1365-2265.2012.04490.x

10.1093/humupd/dmr046

10.1161/ATVBAHA.114.304136

10.1111/cen.12068

TeedeHJ MissoML CostelloMF et al. Technical report for: international evidence‐based guideline for the assessment and management of polycystic ovary syndrome.2018. Available fromhttps://www.monash.edu/__data/assets/pdf_file/0020/1412282/PCOS-Guideline_Technical-report.pdf. Last accessed September 28 2019.

10.1093/humupd/dmaa029

10.1210/clinem/dgab392

10.1016/j.smrv.2016.07.002

10.1530/EC-17-0129

10.1016/j.sleep.2016.12.029

10.1530/EJE-18-0693

10.1093/humrep/dex044

10.1371/journal.pone.0097041

10.1210/jc.2016-3863

10.1210/jc.2011-3357

10.1001/archpsyc.61.1.62

10.1016/j.steroids.2013.04.004

10.1093/humupd/dmu012

10.1016/j.ygyno.2014.11.012

Thông tin
Thông tin xuất bản

Clinical Endocrinology

Tập 97 Số 3

371-382

Thông tin tác giả